Resolution of severe digital ulceration during a course of bosentan therapy [4]

Annals of Internal Medicine

Volumn 142, Issue 9, 2005, Pages 802-803

  Snyder, Michael J ^a   Jacobs, Mary R ^a   Grau, Rafael G ^a   Wilkes, David S ^a   Knox, Kenneth S ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CYCLOPHOSPHAMIDE; METHOTREXATE; PENICILLAMINE; STEROID;

ADULT; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; ESOPHAGUS DISEASE; HUMAN; LETTER; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SKIN ULCER; SYSTEMIC SCLEROSIS; ULCER;

EID: 17844390106     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-142-9-200505030-00029     Document Type: Letter

References (5)

1. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
2. Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxford). 2003;42:191-3.
3. Schachna L, Wigley FM. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol. 2002;14:686-93.
4. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis. 2004;63:1009-14.
5. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985-93.